Expert Review of Clinical Immunology最新文献_第2页

Chronic obstructive pulmonary disease, biological agents and small molecules: where do we stand? 慢性阻塞性肺疾病，生物制剂和小分子：我们站在哪里？

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-06-19 DOI: 10.1080/1744666X.2025.2522266

Carlo Lombardi, Francesco Menzella

{"title":"Chronic obstructive pulmonary disease, biological agents and small molecules: where do we stand?","authors":"Carlo Lombardi, Francesco Menzella","doi":"10.1080/1744666X.2025.2522266","DOIUrl":"10.1080/1744666X.2025.2522266","url":null,"abstract":"Introduction: Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation. A subset of patients exhibits eosinophilic inflammation, which has been shown to impact disease severity and exacerbation frequency.Areas covered: This review aims to provide an update on the role of eosinophils in COPD and the efficacy of biologics targeting inflammation. Furthermore, we will explore eosinophilia as a biomarker for COPD outcomes. The findings highlight the potential of biologics in managing COPD. We conducted a review of the English-language literature from the beginning of the databases reviewed through April 2025.Expert opinion: In COPD there is a close interplay between inflammation, lung damage and multimorbidities, mechanisms that determine a lower efficacy of biologics. Patients currently eligible for biologics are only the subpopulation with eosinophilic airway inflammation, but biologics that target broad-acting epithelial cytokines might have a greater efficacy in a complex disease such as COPD. This is because their mechanism of action is not limited to modulation of eosinophilic inflammation alone but to multiple driver pathways. Looking forward, there is an urgent need to identify new biomarkers for better patient selection to improve the impact of biologics, which is still not yet fully satisfactory.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"909-919"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic polymorphisms and cytokine levels in ischemic stroke: associations with subtypes and prognosis. 缺血性卒中的遗传多态性和细胞因子水平：与亚型和预后的关系。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-06-14 DOI: 10.1080/1744666X.2025.2517164

Gaetano Pacinella, Anna Maria Ciaccio, Alessandra Casuccio, Mario Daidone, Rosaria Pecoraro, Danilo Di Bona, Alessandro Del Cuore, Maria Grazia Puleo, Domenico Di Raimondo, Tiziana Di Chiara, Giuseppe Miceli, Vittoriano Della Corte, Valentina Arnao, Antonino Tuttolomondo

{"title":"Genetic polymorphisms and cytokine levels in ischemic stroke: associations with subtypes and prognosis.","authors":"Gaetano Pacinella, Anna Maria Ciaccio, Alessandra Casuccio, Mario Daidone, Rosaria Pecoraro, Danilo Di Bona, Alessandro Del Cuore, Maria Grazia Puleo, Domenico Di Raimondo, Tiziana Di Chiara, Giuseppe Miceli, Vittoriano Della Corte, Valentina Arnao, Antonino Tuttolomondo","doi":"10.1080/1744666X.2025.2517164","DOIUrl":"10.1080/1744666X.2025.2517164","url":null,"abstract":"Introduction: Some genetic polymorphisms are associated with the risk of stroke, although the individual contribution of such polymorphisms is considered modest.Aims: To evaluate the frequency of single nucleotide polymorphisms (SNPs) in genes encoding proinflammatory cytokines and coagulation factors in stroke patients, the relationships between the serum levels of the cytokines analyzed with stroke subtypes and prognosis.Material and methods: A retrospective, cross-sectional, observational, analytical, case-control study. We performed genetic analysis to evaluate various genetic polymorphisms and analyzed cytokine levels at admission.Results: 429 patients with ischemic stroke and 195 control subjects without ischemic stroke. Patients with CEI subtype showed significantly higher levels of all the cytokines analyzed, namely, IL-10, TNF-alpha, and IL-6. Logistic regression analysis revealed that higher TNF-α (alpha), IL-6, and IL-1 β levels were significantly associated with the LAAS and CEI subtypes. TNF-α, IL-1, and IL-6 levels were significantly higher in patients with recurrent stroke at follow-up. Of the three polymorphisms in the gene encoding PTSG2, the haplotypes rs6275 and rs20417 showed a different distribution between patients and controls.Discussion: The reported association between ischemic stroke and immunoinflammatory variables agrees with previously reported associations between some proinflammatory and prothrombotic polymorphisms and the risk of ischemic stroke.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"961-976"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phosphoinositide-3-kinase δ as an immune check-pathway in cancer Immunology. Therapeutic prospects. 磷酸肌苷-3-激酶δ在肿瘤免疫学中的免疫检查途径。治疗前景。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-07-14 DOI: 10.1080/1744666X.2025.2522265

María Palacios-Ortega, Ángel L Corbí, Blanca García-Solís, Rebeca Pérez de Diego, Macarena Sierra, Miguel Fernández-Arquero, Alberto Ocaña, Pedro Pérez-Segura, Silvia Sánchez-Ramón

{"title":"Phosphoinositide-3-kinase δ as an immune check-pathway in cancer Immunology. Therapeutic prospects.","authors":"María Palacios-Ortega, Ángel L Corbí, Blanca García-Solís, Rebeca Pérez de Diego, Macarena Sierra, Miguel Fernández-Arquero, Alberto Ocaña, Pedro Pérez-Segura, Silvia Sánchez-Ramón","doi":"10.1080/1744666X.2025.2522265","DOIUrl":"10.1080/1744666X.2025.2522265","url":null,"abstract":"Introduction: Phosphoinositide-3-kinase δ (PI3Kδ) is a critical regulator of cellular processes, predominantly within the immune system, and its dysregulation is implicated in inborn errors of immunity, including Activated PI3 Kinase Delta Syndrome (APDS), and various malignancies, including hematological and solid tumors. Given PI3Kδ's predominant expression in leukocytes, its aberrant activation not only promotes tumor growth but also enables immune evasion, underscoring its importance as an 'immune-check pathway,' especially in immune-rich tumor microenvironments.Areas covered: This review examines the oncogenic role of PI3Kδ signaling, emphasizing its contribution to immune evasion, tumor proliferation, survival, and metastasis across different cancers. A bibliographic search was conducted in PubMed, Science Direct, MEDES and SciELO using specific criteria for articles published until 2023.Expert opinion: PI3Kδ signaling can be conceptualized as an immune check pathway, reinforcing its potential as a therapeutic cancer target. Recent clinical trials using PI3Kδ inhibitors have shown efficacy across various cancers (hematological, breast, gynecologic, and digestive cancers), suggesting their applicability beyond APDS and primary malignancies. This approach could prevent cancer-linked immunodeficiency, providing dual therapeutic and prophylactic benefits. Future research should explore PI3Kδ inhibitors as a comprehensive strategy for managing cancer progression and associated immune dysfunction, ultimately improving patient outcomes.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"943-960"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple sclerosis-like manifestations in systemic autoimmune and inflammatory disorders: an update. 系统性自身免疫和炎症性疾病中的多发性硬化症样表现：Αn最新进展。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-07-01 Epub Date: 2025-06-25 DOI: 10.1080/1744666X.2025.2522270

Sylvia Raftopoulou, Ioanna Kapsali, Maria-Eleftheria Evangelopoulos, Clio P Mavragani

{"title":"Multiple sclerosis-like manifestations in systemic autoimmune and inflammatory disorders: an update.","authors":"Sylvia Raftopoulou, Ioanna Kapsali, Maria-Eleftheria Evangelopoulos, Clio P Mavragani","doi":"10.1080/1744666X.2025.2522270","DOIUrl":"10.1080/1744666X.2025.2522270","url":null,"abstract":"Introduction: Multiple sclerosis (MS) is the most recognized CNS autoimmune demyelinating disease, characterized by neuroinflammation, myelin loss, and axonal damage. Due to clinical overlap with several disorders such as systemic autoimmune diseases (SADs), which can closely resemble MS, the diagnostic process can be challenging. SADs with CNS involvement can present with neurological symptoms such as transverse myelitis, optic neuritis, and white matter lesions. This diagnostic uncertainty contributes to a significant rate of misdiagnosis which can lead to improper treatment, worsening symptoms, and increasing disability.Areas covered: In this review, we discuss the physiology of myelin in the CNS, the pathophysiology of MS and other immune-mediated demyelinating diseases that can mimic MS. We also discuss similar presentations between MS and MS-like clinical entities, and their appropriate treatment regimes.Expert opinion: SADs and other clinical entities are key MS mimickers, significantly complicating diagnosis at a first neurological episode. Careful clinical evaluation, imaging, and exclusion of alternative diagnoses are crucial to avoid misdiagnosis. Understanding the subtle distinctions between MS and SADs and looking out for, and further investigating atypical presentations, is vital for ensuring accurate diagnosis and proper treatment, thereby improving patient outcomes and reducing unnecessary disability.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"855-873"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biologics for severe asthma: deciphering what is best for the patient. 治疗严重哮喘的生物制剂：解读什么对患者最好。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-06-30 DOI: 10.1080/1744666X.2025.2525443

Mario Cazzola, Nicola A Hanania, Maria Gabriella Matera, Paola Rogliani

{"title":"Biologics for severe asthma: deciphering what is best for the patient.","authors":"Mario Cazzola, Nicola A Hanania, Maria Gabriella Matera, Paola Rogliani","doi":"10.1080/1744666X.2025.2525443","DOIUrl":"10.1080/1744666X.2025.2525443","url":null,"abstract":"Introduction: Choosing the right biologic for the right patient is challenging. It requires evaluating patient characteristics and disease manifestations, understanding the scientific evidence supporting each biologic's efficacy and safety, and using a shared decision-making strategy with the patient.Areas covered: Based on a comprehensive review of the literature, in this narrative review we explore the latest approaches on the optimal selection of biologics in severe asthma.Expert opinion: Biologics target different inflammatory pathways. The choice of biologic depends on biomarker profiles, clinical phenotype and endotype of the disease and its associated comorbidities. A structured approach using biomarkers is essential to guide personalized treatment decisions. Exacerbation history, corticosteroid dependence, and comorbidities all influence therapeutic selection. Asthma is challenging to treat because it is heterogeneous, symptoms change over time and biomarkers lack precision. Researchers are recognizing the need for combination biologic therapy and improved biomarker-driven strategies. However, biologic selection is complex due to overlapping inflammatory pathways and variable treatment response. Emerging strategies, including multi-biomarker panels, multi-omics approaches, and machine learning-driven decision making, aim to refine asthma phenotyping/endotyping and thus optimize treatment outcomes. Real-world studies, pragmatic clinical trials, and head-to-head comparisons of biologics are key to advancing precision medicine and improving long-term asthma management.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-20"},"PeriodicalIF":3.9,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TFDP1 activates SPC25-mediated glutamine metabolism to repress anti-tumor immunity of NK cells in lung adenocarcinoma. TFDP1激活spc25介导的谷氨酰胺代谢，抑制肺腺癌NK细胞的抗肿瘤免疫。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-06-25 DOI: 10.1080/1744666X.2025.2524469

Bin Huang, Keng Chen, Mingjiang Huang, Zhangyong Yin, Wei He, Xuyang Peng, Gongzhi Wu, Jianyang Ding, Congxiong Peng, Xuhui Wu

{"title":"TFDP1 activates SPC25-mediated glutamine metabolism to repress anti-tumor immunity of NK cells in lung adenocarcinoma.","authors":"Bin Huang, Keng Chen, Mingjiang Huang, Zhangyong Yin, Wei He, Xuyang Peng, Gongzhi Wu, Jianyang Ding, Congxiong Peng, Xuhui Wu","doi":"10.1080/1744666X.2025.2524469","DOIUrl":"10.1080/1744666X.2025.2524469","url":null,"abstract":"Objectives: The main purpose of this study is to investigate the specific role of SPC25 in the anti-tumor immune process of Natural killer (NK) cells in lung adenocarcinoma (LUAD).Methods: The differentially expressed gene SPC25 was screened by the Cancer Genome Atlas database. The effect of SPC25 on the anti-tumor immunity of NK cells was evaluated by immunofluorescence, flow cytometry, lactate dehydrogenase kit, and enzyme-linked immunosorbent assay. The influence of SPC25 on glutamine (GLN) metabolism was examined by the GLN metabolism-related kit and Western blot. The interaction between SPC25 and TFDP1 was assessed by luciferase reporter gene detection and ChIP.Results: SPC25 was overexpressed in LUAD (p < 0.0001), being capable of reducing levels of cytotoxicity and cytokines in NK cells. SPC25 repressed the function of NK cells by activating GLN metabolism (p < 0.0001). Mechanistically, TFDP1 was a transcriptional activator of SPC25. Knocking down TFDP1 hindered GLN metabolism (p < 0.05) and potentiated NK cell killing ability against LUAD cells, while overexpression of SPC25 reversed the effects of TFDP1 knockdown.Conclusion: This study intended to verify the inhibitory effect of TFDP1 on NK cell anti-tumor immunity by activating SPC25-mediated LUAD glutamine metabolism.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-11"},"PeriodicalIF":3.9,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IL-17A in psoriatic arthritis: mechanistic insights, clinical implications, and advances in therapeutic strategies. IL-17A在银屑病关节炎中的作用：机制、临床意义和治疗策略的进展

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-06-24 DOI: 10.1080/1744666X.2025.2522950

Francesco Caso, Anella Saviano, Noemi Marigliano, Gian Marco Casillo, Michele Peluso, Miriam Ciccone, Simona Serao Creazzola, Teresa D'Agostino, Adel Abo Mansour, Marco Tasso, Mario Cascone, Matteo Megna, Asif Jilani Iqbal, Raffaele Scarpa, Luisa Costa, Francesco Maione

{"title":"IL-17A in psoriatic arthritis: mechanistic insights, clinical implications, and advances in therapeutic strategies.","authors":"Francesco Caso, Anella Saviano, Noemi Marigliano, Gian Marco Casillo, Michele Peluso, Miriam Ciccone, Simona Serao Creazzola, Teresa D'Agostino, Adel Abo Mansour, Marco Tasso, Mario Cascone, Matteo Megna, Asif Jilani Iqbal, Raffaele Scarpa, Luisa Costa, Francesco Maione","doi":"10.1080/1744666X.2025.2522950","DOIUrl":"10.1080/1744666X.2025.2522950","url":null,"abstract":"Introduction: Psoriatic arthritis (PsA) is an immune-inflammatory disease involving skin and synovial-entheseal compartments. The understanding of IL-17 biological function has revolutionized the understanding of PsA pathogenesis and, consequently, its therapeutic approach.Areas covered: In this review article, we have outlined the primary evidence regarding the biological functions of IL-17A in PsA, and summarized data from randomized controlled trials (RCTs) on PsA and psoriasis approved secukinumab, ixekizumab, bimekizumab, brodalumab, and emerging IL-17 inhibitors.Expert opinion: The biologic disease-modifying antirheumatic drugs (bDMARDs), secukinumab, and ixekizumab target interleukin-17A (IL-17A), and bimekizumab, which simultaneously neutralizes IL-17A and IL-17F, have demonstrated efficacy in treating both peripheral and axial articular manifestations of PsA, as well in improving skin involvement, enthesitis and dactylitis. Brodalumab, which inhibits the IL-17 receptor A (IL-17RA), represent an efficacious strategy for psoriasis.Continued research into the role of IL-17s in PsA pathogenesis is crucial for improving our understanding of the disease and developing more effective therapeutic strategies. Further research and advancements in biologic therapies will refine IL-17 inhibitory strategies, potentially improving outcomes for PsA patients, and other immune-mediated diseases.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-17"},"PeriodicalIF":3.9,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The interplay between asthma and type 2 diabetes mellitus: mutual interactions and therapeutic implications. 哮喘和2型糖尿病的相互作用：相互作用和治疗意义。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-06-10 DOI: 10.1080/1744666X.2025.2514607

Mario Cazzola, Nicola A Hanania, Clive P Page, Luigino Calzetta, Maria Gabriella Matera, Paola Rogliani

{"title":"The interplay between asthma and type 2 diabetes mellitus: mutual interactions and therapeutic implications.","authors":"Mario Cazzola, Nicola A Hanania, Clive P Page, Luigino Calzetta, Maria Gabriella Matera, Paola Rogliani","doi":"10.1080/1744666X.2025.2514607","DOIUrl":"10.1080/1744666X.2025.2514607","url":null,"abstract":"Introduction: Asthma and type 2 diabetes mellitus (T2DM) are chronic diseases with a significant global health burden. Recent studies have highlighted the complex relationship between these two diseases, particularly regarding their pharmacological management.Areas covered: This review discusses the mechanisms linking asthma and T2DM and the interactions between asthma and T2DM therapies, highlighting the potential clinical implications. We examine the effects of asthma medications on glycemic control and diabetes management and review the effects of commonly used T2DM medications on outcomes in patients with asthma.Expert opinion: Effectively managing asthma and T2DM requires an understanding of the beneficial and adverse effects of asthma drugs on glucose metabolism. It is also essential to consider the potential benefits of diabetes treatments on respiratory health and the impact of obesity on both diseases. Such knowledge can facilitate the optimization of drug plans and the minimization of adverse effects, while exploiting potential synergies between treatments for these diseases. However, to improve understanding of the complex mechanisms underlying the interaction between these chronic diseases, further research using a comprehensive approach that includes inflammatory pathways, metabolic factors, therapeutic interventions, gender differences, and lifestyle influences is needed.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"683-699"},"PeriodicalIF":3.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between inactivated COVID-19 vaccine and semen quality among males recovered from omicron infection: a retrospective cohort study. COVID-19灭活疫苗与组粒感染后恢复男性精液质量的关系：一项回顾性队列研究

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-05-26 DOI: 10.1080/1744666X.2025.2507329

Yunlong Li, Yinxia Su, Yangchang Zhang, Zihao Guo, Zhaoyun Chen, Hui Li, Chunyang Zhang, Qiaoge Chi, Yang Ge, Mohammad Javanbakht, Salihu S Musa, Shengzhi Sun, Naijun Tang, Kai Wang, Kailu Wang, Shi Zhao

{"title":"Association between inactivated COVID-19 vaccine and semen quality among males recovered from omicron infection: a retrospective cohort study.","authors":"Yunlong Li, Yinxia Su, Yangchang Zhang, Zihao Guo, Zhaoyun Chen, Hui Li, Chunyang Zhang, Qiaoge Chi, Yang Ge, Mohammad Javanbakht, Salihu S Musa, Shengzhi Sun, Naijun Tang, Kai Wang, Kailu Wang, Shi Zhao","doi":"10.1080/1744666X.2025.2507329","DOIUrl":"10.1080/1744666X.2025.2507329","url":null,"abstract":"Background: The protective effects of inactivated COVID-19 vaccines against SARS-CoV-2-associated semen impairment remain underexplored. We aimed to investigate the association between BBIBP-CorV vaccination and semen quality in males recovering from SARS-CoV-2 infection.Research design and methods: This single-center retrospective cohort study included males recovering from SARS-CoV-2 infection at a tertiary hospital in Urumqi, China (February-May 2023). Participants were categorized into long-term (> 90 days) and short-term (≤ 90 days) effects groups based on the interval between semen collection and their most recent SARS-CoV-2 infection. The study assessed the association between different doses of BBIBP-CorV vaccination and semen quality in both groups.Results: A total of 1496 participants were recruited for the short-term (n = 307) and long-term effect groups (n = 1189). Participants had a median age of 32 (IQR: 30, 35) years. Compared to unvaccinated controls, 2-dose and 3-dose recipients showed reduced risk of semen quality impairment in short-term, with adjusted relative risk (RR) of 0.945 (95% CI 0.918, 0.973) and 0.965 (95% CI 0.937, 0.993), respectively. No significant results were found for long-term effect groups.Conclusion: Inactivated COVID-19 vaccination may protect against semen quality impairment in males recovering from SARS-CoV-2 Omicron infection within 90 days, particularly in semen volume and sperm progressive motility.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"825-834"},"PeriodicalIF":3.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mycosis fungoides and IL-4/13 inhibitors: what is known and unmet needs. 蕈样真菌病和IL-4/13抑制剂：已知和未满足的需求。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-05-17 DOI: 10.1080/1744666X.2025.2507332

Alba Guglielmo, Alessandro Borghi, Natale Schettini, Marcello Perillo, Monica Corazza, Bianca Maria Piraccini, Alessandro Pileri

{"title":"Mycosis fungoides and IL-4/13 inhibitors: what is known and unmet needs.","authors":"Alba Guglielmo, Alessandro Borghi, Natale Schettini, Marcello Perillo, Monica Corazza, Bianca Maria Piraccini, Alessandro Pileri","doi":"10.1080/1744666X.2025.2507332","DOIUrl":"10.1080/1744666X.2025.2507332","url":null,"abstract":"Introduction: Dupilumab is a monoclonal antibody that inhibits the IL-4 receptor alpha, preventing the binding of IL-4 and IL-13 and the subsequent signal transduction. Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common form of cutaneous T-cell lymphoma (CTCL). Several cases of MF have been reported following the initiation of dupilumab in patients previously diagnosed with atopic dermatitis.Areas covered: This article is a narrative review of the current state of knowledge regarding the correlation between dupilumab and the development of CTCL. Clinical studies on this topic are reviewed, with a particular focus on the pathogenetic theories proposed to date. Finally, we present a new theory, previously undescribed, regarding the potential role of the cytokine microenvironment in triggering CTCL in patients treated with dupilumab.Expert opinion: Dupilumab could unmask CTCLs by inhibiting IL-4. In fact, a recent study observed that IL-4 plays a key role in maintaining the 'equilibrium phase' between tumor and microenvironment cells. Disruption of this balance could promote the escape of tumor cells and lead to the unmasking of CTCLs.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"723-729"},"PeriodicalIF":3.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0